

Series: [Advances in Health Sciences Research](#)

Proceedings of the 1st Lawang Sewu International Symposium 2022 on Health Sciences (LSISHS 2022)

[HOME](#)

[PREFACE](#)

[ARTICLES](#)

[AUTHORS](#)

[SESSIONS](#) ▼

[ORGANIZERS](#)

[< PREVIOUS VOLUME IN SERIES](#)

Welcome to 1st Lawang Sewu International Symposium 2022 on Health Sciences is an annual international symposium held by Universitas Muhammadiyah Semarang. The study focused on Health Sciences are welcome. The submitted papers must meet the criteria including originality, novelty, not yet published, and must be written in English language. Symposium will be held through online due to Covid-19 pandemic situation.

Part of **SPRINGER NATURE**

[PROCEEDINGS](#) | [JOURNALS](#) | [BOOKS](#)

Search

Advances in Health Sciences Research

SERIES HOME

ISSN (Online):

2468-5739

ISSN (Print):

N/A

Series Editor(s):

vacant

NEW CONTENT ALERTS



The proceedings series *Advances in Health Sciences Research* aims to publish proceedings from conferences in fields of health sciences and health professions and those addressing the use of science and technology in the delivery of healthcare. [Read full Aims & Scope](#)

All proceedings in this series are **open access**, i.e. the articles published in them are immediately and permanently free to read, download, copy & distribute. Each volume is

published under the **CC BY-NC 4.0** user license which defines the permitted 3rd-party reuse of its articles. The online publication of each proceedings is sponsored by the conference organizers and hence no additional publication fees are required.

Should you wish to publish a proceedings in this series, then please request a proceedings proposal form by sending an email to contact@atlantis-press.com. Your proposal will be evaluated by a Series Editor(s) and/or a scientific evaluation committee consisting of senior researchers in the relevant field. This is to ensure the integrity and quality of the proceedings that we publish.

For any questions about this series, please [contact our publishing team](#).

Latest Volumes

Most Downloaded

Most Cited

Upcoming Volumes

Proceedings of the 1st Lawang Sewu International Symposium 2022 on Health Sciences (LSISHS 2022)

Editors: Satriya Pranata; Purnomo Purnomo; Sri Rejeki; Yanuan Ben Olina</br></br>

Volume 60, April 2023

For more information, please contact us at: contact@atlantis-press.com

▶ PROCEEDINGS

▶ JOURNALS

▶ BOOKS

▶ POLICIES

▶ MANAGE COOKIES/DO NOT SELL MY INFO

▶ ABOUT

▶ NEWS

▶ CONTACT

▶ SEARCH

[Home](#) [Privacy Policy](#) [Terms of use](#)   

Copyright © 2006-2023 Atlantis Press – now part of Springer Nature

Part of **SPRINGER NATURE**

[PROCEEDINGS](#) | [JOURNALS](#) | [BOOKS](#)

Search

Series: [Advances in Health Sciences Research](#)

Proceedings of the 1st Lawang Sewu International Symposium 2022 on Health Sciences (LSISHS 2022)

PROCEEDINGS OF THE 1ST LAWANG SEWU INTERNATIONAL SYMPOSIUM 2022 ON HEALTH SCIENCES (LSISHS 2022)



Analysis of Genetic Characterization and Phylogenetic of SARS-CoV-2 from Manokwari West Papua

Authors

Mudyawati Kamaruddin^{1,*}, Muhamad Fazri¹, Hana Hapsari², Risa Umami¹, Ardi Pranata³, Ayi Suwarai⁴, Era Maryani⁴, Nurul Cahyani Amir⁴, Ratnasari Dewi⁵, Nurhidayat Triananinsi⁶

¹ Postgraduate Program of Clinical Laboratory Sciences, Muhammadiyah Semarang University, Semarang, Central Java, Indonesia

² Indonesia Ministry of Health Research and Development, Jakarta, Indonesia

³ Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Muhammadiyah Semarang University, Semarang, Central Java, Indonesia

⁴ Molecular Laboratory, Central Hospital of Manokwari, West Papua, Indonesia

⁵ Health Polytechnic of Health Ministry, Makassar, South Sulawesi, Indonesia

⁶ Midwifery Program of Megarezky University, Makassar, South Sulawesi, Indonesia

* Corresponding author. Email: mudyawati@unimus.ac.id

Corresponding Author

Mudyawati Kamaruddin

Available Online 19 April 2023.

DOI

[10.2991/978-94-6463-132-6_26](https://doi.org/10.2991/978-94-6463-132-6_26) [How to use a DOI?](#)

Keywords

CoViD-19; Genetic Characterization; Phylogenetic; Virus Variants

Abstract

Genome analysis is critical for tracking the spread of the CoVid-19 virus throughout Indonesia. Considering that Indonesia is an archipelago, the demographics of each province will create different virus variance results. The genome sequence, virus variants, and phylogenetic description of the SARS-CoV-2 strain from Manokwari, West Papua, are being determined urgently. The entire genome was sequenced using the Reagan Illumina COVIDSeq and the sequencing by synthesis (SBS) method. Annotation of the entire viral genome using the hCoV-19/Wuhan/Hu-1/2019 reference genome (NC 045512.2). Phylogenetic analysis was performed on 54 SARS-CoV-2 genomes obtained from GISAID in Indonesia and other countries. The virus strains found in Manokwari, West Papua, are Delta (B.1.617.2), B.1.466.2, and Omicron (BA.1, BA.1.15, and BA.1.13.1). The SARS-CoV-2 strain from Manokwari is classified into VOC and VUM variants based on the WHO variant classification. According to the results of genetic

characterization analysis, the ORF1ab NSP3 gene, ORF3 gene, ORF7 gene, N gene, and S gene had the most mutations. The West Papua strain of SARS-CoV-2 Manokwari has ten clades, with the B.1.466.2 virus variant adjacent to the B.1.466.2 virus variant from Southeast Sulawesi and West Sumatra, according to the phylogenetic analysis of virus variants. The Manokwari West Papua SARS-CoV-2 virus strain has three variants: Delta (B.1.617.2), B.1.466.2, and Omicron (BA.1, BA.1.15 and BA.1.13.1).

Copyright

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

[+ Download article \(PDF\)](#)



Volume Title

Proceedings of the 1st Lawang Sewu International Symposium 2022 on Health Sciences (LSISHS 2022)

Series

Advances in Health Sciences Research

Publication Date

19 April 2023

ISBN

10.2991/978-94-6463-132-6_26

ISSN

2468-5739

DOI[10.2991/978-94-6463-132-6_26](https://doi.org/10.2991/978-94-6463-132-6_26) [How to use a DOI?](#)**Copyright**

© 2023 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

ris

enw

bib

TY - CONF
AU - Mudyawati Kamaruddin
AU - Muhamad Fazri
AU - Hana Hapsari
AU - Risa Umami
AU - Ardi Pranata
AU - Ayi Suwarai
AU - Era Maryani
AU - Nurul Cahyani Amir
AU - Ratnasari Dewi
AU - Nurhidayat Triananinsi
PY - 2023
DA - 2023/04/19
TI - Analysis of Genetic Characterization and Phylogenetic of SARS-CoV-2 from Manokwari West Papua
BT - Proceedings of the 1st Lawang Sewu International Symposium 2022 on Health Sciences (LSISHS 2022)
PB - Atlantis Press
SP - 221
EP - 233
SN - 2468-5739
UR - https://doi.org/10.2991/978-94-6463-132-6_26
DO - 10.2991/978-94-6463-132-6_26
ID - Kamaruddin2023
ER -

 [download .ris](#)

[COPY TO CLIPBOARD](#)

Atlantis Press

Atlantis Press – now part of Springer Nature – is a professional publisher of scientific, technical & medical (STM) proceedings, journals and books. We offer world-class services, fast turnaround times and personalised communication. The proceedings and journals on our platform are Open Access and generate millions of downloads every month.

For more information, please contact us at: contact@atlantis-press.com

- ▶ PROCEEDINGS
- ▶ JOURNALS
- ▶ BOOKS
- ▶ POLICIES
- ▶ MANAGE COOKIES/DO NOT SELL MY INFO
- ▶ ABOUT
- ▶ NEWS
- ▶ CONTACT
- ▶ SEARCH

[Home](#) [Privacy Policy](#) [Terms of use](#)   

Copyright © 2006-2023 Atlantis Press – now part of Springer Nature



Analysis of Genetic Characterization and Phylogenetic of SARS-CoV-2 from Manokwari West Papua

Mudyawati Kamaruddin¹✉, Muhamad Fazri¹, Hana Hapsari², Risa Umami¹,
Ardi Pranata³, Ayi Suwarai⁴, Era Maryani⁴, Nurul Cahyani Amir⁴, Ratnasari Dewi⁵,
and Nurhidayat Triananinsi⁶

- ¹ Postgraduate Program of Clinical Laboratory Sciences, Muhammadiyah Semarang University,
Semarang, Central Java, Indonesia
mudyawati@unimus.ac.id
- ² Indonesia Ministry of Health Research and Development, Jakarta, Indonesia
- ³ Medical Laboratory Technology, Faculty of Nursing and Health Sciences, Muhammadiyah
Semarang University, Semarang, Central Java, Indonesia
- ⁴ Molecular Laboratory, Central Hospital of Manokwari, West Papua, Indonesia
- ⁵ Health Polytechnic of Health Ministry, Makassar, South Sulawesi, Indonesia
- ⁶ Midwifery Program of Megarezky University, Makassar, South Sulawesi, Indonesia

Abstract. Genome analysis is critical for tracking the spread of the CoVid-19 virus throughout Indonesia. Considering that Indonesia is an archipelago, the demographics of each province will create different virus variance results. The genome sequence, virus variants, and phylogenetic description of the SARS-CoV-2 strain from Manokwari, West Papua, are being determined urgently. The entire genome was sequenced using the Reagen Illumina COVIDSeq and the sequencing by synthesis (SBS) method. Annotation of the entire viral genome using the hCoV-19/Wuhan/Hu-1/2019 reference genome (NC 045512.2). Phylogenetic analysis was performed on 54 SARS-CoV-2 genomes obtained from GISAID in Indonesia and other countries. The virus strains found in Manokwari, West Papua, are Delta (B.1.617.2), B.1.466.2, and Omicron (BA.1, BA.1.15, and BA.1.13.1). The SARS-CoV-2 strain from Manokwari is classified into VOC and VUM variants based on the WHO variant classification. According to the results of genetic characterization analysis, the ORF1ab NSP3 gene, ORF3 gene, ORF7 gene, N gene, and S gene had the most mutations. The West Papua strain of SARS-CoV-2 Manokwari has ten clades, with the B.1.466.2 virus variant adjacent to the B.1.466.2 virus variant from Southeast Sulawesi and West Sumatra, according to the phylogenetic analysis of virus variants. The Manokwari West Papua SARS-CoV-2 virus strain has three variants: Delta (B.1.617.2), B.1.466.2, and Omicron (BA.1, BA.1.15 and BA.1.13.1).

Keywords: CoViD-19 · Genetic Characterization · Phylogenetic · Virus Variants

1 Introduction

The severe acute respiratory syndrome coronavirus two (SARS-CoV-2) virus has spread and increased at an alarming rate since its discovery in mainland China. On March 2, 2020, this virus was detected and caused several reported cases of COVID-19 in Indonesia [1]. Since then, confirmed cases have continued to be investigated, despite several public health measures to stop the spread of COVID-19, such as the isolation of confirmed patients and the implementation of strictly enforced health protocols in the community. As of November 17, 2021, there were 255,103,209 confirmed cases and 5,126,415 deaths, with a COVID-19 incidence of 621,943 per 100,000 people. There are confirmed cases in Indonesia until November 17, 2021, with 4,251,945 people infected and 143,698 deaths [2].

West Papua Province in eastern Indonesia was not spared from the spread of the SARS-CoV-2. There were 23,135 confirmed positive patients until November 17, 2021, with 357 deaths. The rapid spread of SARS-CoV-2 in different regions resulted in mutation-driven evolution. Genomes with new variants emerged when the virus moved across different environmental conditions; thus, genomic surveillance of viral mutations is essential. SARS-CoV-2 mutations have spread faster than the previous strain until now. Furthermore, SARS-CoV-2 mutations are known to be caused by changes in genetic material (in the form of nucleotide bases), which result in phenotypic differences from the original virus [4]. Changes in the nature of the virus can affect how quickly it spreads, the severity of the existing complications, and the efficacy of vaccines, active ingredients, test equipment, and health measures. The phenotypic differences in SARS-CoV-2 caused by mutations are used to identify a variant. Active variants are currently being monitored globally to ensure that if significant amino acid substitutions are discovered, immediate action is taken to respond to these variants and prevent their spread [6]. The SARS-CoV-2 Evolution Working Group (SEWG) of the WHO established three levels of variants based on the level of alertness and the risk of decreased diagnostic, therapeutic, and vaccine efficacy, namely SARS-CoV-2, which has been shown to change in phenotypic properties. Because of mutations that have been identified and spread within a community or detected in multiple countries [6].

Based on Indonesian WGS data as of June 13, 2021 a total of 1,908 complete genome sequences were reported that the new SARS-CoV-2 virus variant in Indonesia was the Variant of Concern, consisting of Alpha (B.117) in 35 cases, Beta (B.1.351) in 5 cases, and Delta (B.1.617.2) in 50 cases. Variant of Interest, consisting of A.23.1 (6 cases), Eta (B.1.525) (4 cases), and B.1.617.3 (1 case). WGS data as of 17 November 2021 increased to 8,856 sequences, with a significant increase from VOC such as alpha (B.117) to 77 cases, beta (B.1.351) (22 cases), and delta (B.1.617.2) (4,977 cases). So far, variant mutations in Indonesia included B.1.621, Lamda, Gamma, Beta, Alpha, Delta, B.1.640, and Omicron (GISAID, 2021).

According to the WGS data, the number of SARS-CoV-2 sequences until November 2021 was still very low (0.2%) when compared to the number of confirmed COVID-19 patients. More variants will be confirmed if the SARS-CoV-2 genome is sequenced further. As a result, it is critical to conduct research on the complete genome sequence and phylogenetics of the SARS-CoV-2 virus collected in Manokwari, West Papua. The

goal of this study was to characterize the complete genome sequence and variants of the SARS-CoV-2 virus Manokwari, West Papua.

2 Methods

2.1 CoViD-19 Samples

All virus samples were obtained from SARS-CoV-2 patients' nasopharyngeal and oropharyngeal swabs at the West Papua Provincial General Hospital.

Viral RNA was extracted from nasopharyngeal samples using the taco extraction kit reagent and following the kit's instructions, which included pipetting 200 μ l of the sample and inserting it into the sample wells on the extraction plate for 45 min. Following the completion of the extraction process, 200 μ l of RNA is added to the sample stamp, and the RNA is ready for use.

2.2 CoViD-19 Samples

Whole Genome Sequencing (WGS) was performed on 48 samples in VTM tubes that met the criteria at the Prof. Srie Oemijati National Laboratory, Health Development Policy Agency (BKPK) of the Ministry of Health in Jakarta. The Illumina COVIDSeq reagent and the sequencing by synthesis (SBS) method were used in the WGS process. The procedure begins with RNA extraction, followed by Anneal RNA using random hexamers to prepare for cDNA synthesis. To reverse transcribe the RNA fragments, cDNA synthesis was performed according to the manufacturer's instructions.

The target was amplified in two separate PCR reactions using CPP1 HT primer (COVIDSeq Primary Pool 1 HT) and CPP2 HT primer (COVIDSeq Primer Pool 2 HT). During this process, the preparatory library, assembling, and quantification are carried out step by step, and the amplification product is fragmented and tagged with adapters. The fragment that has been given an adapter will be amplified again in order to multiply the fragments, and the libraries will then be indexed and purified. The libraries were measured using the Qubit High Sensitivity dsDNA Quantification Kit with 4nM quantification requirements after purification. In the flow cell, sequencing libraries will assemble [3].

2.3 Genome Analysis

The hCoV-19/Wuhan/Hu-1/2019 (NC 045512.2) reference genome was used to annotate the full-length viral genome. 54 genomes of the SARS-CoV-2 virus from Indonesia and other countries were used for phylogenetic analysis. This information was obtained from gene Bank (GISAID). Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Kappa (B.1.617.2), Epsilon (B.1.427), Eta (B.1.525), Iota (B.1.526), Lambda (C.37), Mu (B.1.621), Omicron (BA.1), B.1.177, 19B, and B.1.466.2 are the viral variants used. The MAFFT program server (<https://mafft.cbrc.jp/alignment/server/>) was used for nucleotide sequence alignment. With a nucleotide length of 29,400, a phylogenetic tree is constructed. All analyses were carried out using the Geneious Prime software

(Kumar et al., 2018). The tree is rooted in the oldest virus, hCoV-19/Wuhan/Hu-1/2019 [2], because the goal of this phylogenetic analysis was to determine the evolutionary relationship between virus samples from the West Papua Provincial Hospital and other SARS-CoV-2 viruses.

3 Results

All virus samples were collected from nasopharyngeal and oropharyngeal swabs of patients who received SARS-CoV-2 testing at the West Papua Province General Hospital, with the sample criteria being people who had been vaccinated, had not been vaccinated against SARS-CoV-2 but were infected with COVID-19, and positive with a CT value of 25. RT-PCR testing was performed on the samples at the Molecular Laboratory of the Regional General Hospital of West Papua Province.

Based on the RT-PCR results, a total of 48 samples were used for Whole Genome Sequencing, which was performed at the Prof. Srie Oemijati Research Center, Health Development Policy Agency (BKPK), Ministry of Health in Jakarta. Whole genome sequencing analysis yielded 32 completely sequenced samples. There were 12 women and 20 men among the 32 samples. Meanwhile, there were 19 adults, 2 teenagers, 5 children, and 1 baby. There were 13 people with blood type O, 4 with blood type A, 7 with blood type B, and 3 with blood type AB, with the remaining 5 people having no known blood type. The vaccines used were generally the Sinovac vaccine for 19 people, the AstraZeneca vaccine for 5 people, and the unvaccinated vaccine for 8 people (Table 1).

Various points of mutation were discovered from the ORF1ab NSP3 gene region to the N gene using characterization analysis of the reference genome from Wuhan, China. Furthermore, the number of nucleotide base changes in the SARS-CoV-2 virus, Manokwari strain from West Papua, was determined. When the SARS-CoV-2 virus sequence from the Manokwari strain was compared to other sequences from Papua, several different mutation points are found.

The key mutation in the S gene for the B.1.466.2 virus variant is in the N439K region, while it is in the L452R and P681R regions for the Delta virus variant, and it is in the K417N, S477N, N501Y, and P681H regions for the omicron virus variant. The Delta Strain Manokwari virus variant did not have mutations in T95I, whereas four samples in G142D did, namely samples no 15, 20, 23, and 25. There were no mutations in the E156G and Del157/158 regions other than this Manokwar strain. Meanwhile, the Omicron virus variant (BA.1.13.1) lacks mutations in the DelN211 and G496S regions, and the Omicron virus variant (BA.1.15) lacks mutations in the DelN211 and G496S regions as well N440K and G446S.

Table 1. An investigation of the SARS-CoV-2 virus of Manokwari West Papua

No	ID Viruses	Sex	Age (y.o)	Ct Value	Blood Type	Vaccine Type	Symptoms
1	MKW_EPI_ISL_3151603	F	31	15,74	A	Sinovac	ODP
2	MKW_EPI_ISL_3151608	M	39	18,43	O	Sinovac	ODP
3	MKW_EPI_ISL_3151615	F	48	21,3	O	Sinovac	ODP
4	MKW_EPI_ISL_3151622	F	64	23,13	O	Sinovac	ODP
5	MKW_EPI_ISL_5022912	F	21	19,55	B	Sinovac	ODP
6	MKW_EPI_ISL_3151635	M	41	17,12	O	Sinovac	ODP
7	MKW_EPI_ISL_3151655	M	11	25,26	–	–	ODP
8	MKW_EPI_ISL_3151661	M	15	19,42	–	–	ODP
9	MKW_EPI_ISL_3278295	F	11	18,43	–	–	ODP
10	MKW_EPI_ISL_3151602	F	40	21,04	AB	AstraZeneca	OTG
11	MKW_EPI_ISL_3151607	F	35	19,23	O	Sinovac	OTG
12	MKW_EPI_ISL_3151614	M	38	23,01	O	AstraZeneca	ODP
13	MKW_EPI_ISL_3151621	M	21	19,23	B	Sinovac	OTG
14	MKW_EPI_ISL_3151628	F	30	20,15	A	Sinovac	OTG
15	MKW_EPI_ISL_3151634	M	15	16,19	–	–	OTG
16	MKW_EPI_ISL_3151641	M	35	18,25	O	Sinovac	ODP
17	MKW_EPI_ISL_3151642	M	43	19,47	B	AstraZeneca	OTG
18	MKW_EPI_ISL_3151647	F	14	20,19	–	–	ODP
19	MKW_EPI_ISL_3151648	M	28	23,17	O	Sinovac	ODP
20	MKW_EPI_ISL_3151653	F	18	22,19	O	–	ODP
21	MKW_EPI_ISL_3151654	F	54	20,79	B	Sinovac	ODP
22	MKW_EPI_ISL_3151659	M	35	25,21	AB	Sinovac	OTG
23	MKW_EPI_ISL_3151660	M	1	20,32	–	–	ODP
24	MKW_EPI_ISL_3151667	M	19	18,27	A	Sinovac	OTG
25	MKW_EPI_ISL_3151668	F	27	21,48	O	AstraZeneca	OTG
26	MKW_EPI_ISL_3151674	M	23	23,19	B	Sinovac	ODP
27	MKW_EPI_ISL-3151675	M	31	20,25	O	Sinovac	ODP

ODP: People in monitoring of CoViD-19

OTG: People without symptoms

Table 2. SNP and variant analysis of the SARS-CoV-2 virus strain Manokwari, West Papua

No	ID Virus	SNP	MISSENSE	SILENT	Varian
1	MKW_EPI_ISL_3151603	25	32	21	B.1.466.2
2	MKW_EPI_ISL_3151608	26	37	21	B.1.466.2
3	MKW_EPI_ISL_3151622	26	33	23	B.1.466.2
4	MKW_EPI_ISL_3151655	34	43	38	B.1.466.2
5	MKW_EPI_ISL_3151661	24	37	22	B.1.466.2
6	MKW_EPI_ISL_3278295	30	48	21	B.1.466.2
7	MKW_EPI_ISL_3151602	28	42	22	B.1466.2
8	MKW_EPI_ISL_3151621	29	42	26	B.1466.2
9	MKW_EPI_ISL_3151641	26	37	22	B.1.466.2
10	MKW_EPI_ISL_3151642	27	37	19	B.1.466.2
11	MKW_EPI_ISL_3151647	26	37	20	B.1.466.2
12	MKW_EPI_ISL_3151653	27	41	24	B.1.466.2
13	MKW_EPI_ISL_3151659	26	41	20	B.1.466.2
14	MKW_EPI_ISL_3151660	26	4	23	B.1.466.2
15	MKW_EPI_ISL_5022912	43	60	25	Delta (B.1.617.2)
16	MKW_EPI_ISL_3151635	31	49	9	Delta (B.1.617.2)
17	MKW_EPI_ISL_3151615	39	65	17	Delta (B.1.617.2)
18	MKW_EPI_ISL_3151607	38	66	16	Delta (B.1.617.2)
19	MKW_EPI_ISL_3151614	38	61	13	Delta (B.1.617.2)
20	MKW_EPI_ISL_3151628	33	40	15	Delta (B.1.617.2)
21	MKW_EPI_ISL_3151634	38	60	16	Delta (B.1.617.2)
22	MKW_EPI_ISL_3151648	43	71	22	Delta (B.1.617.2)
23	MKW_EPI_ISL_3151654	43	71	18	Delta (B.1.617.2)
24	MKW_EPI_ISL_3151667	41	65	20	Delta (B.1.617.2)
25	MKW_EPI_ISL_3151668	42	71	20	Delta (B.1.617.2)
26	MKW_EPI_ISL_3151674	36	61	13	Delta (B.1.617.2)
27	MKW_EPI_ISL-3151675	34	43	18	Delta (B.1.617.2)
28	MKW_EPI_ISL-11994142	58	62	23	Omicron (BA.1.13.1)
29	MKW_EPI_ISL-11994116	57	60	28	Omicron (BA.1)
30	MKW_EPI_ISL-11994140	58	62	23	Omicron (BA.1)
31	MKW_EPI_ISL-11994141	57	63	26	Omicron (BA.1.15)
32	MKW_EPI_ISL-11994143	57	61	24	Omicron (BA.1)




Fig. 1. The West Papua Manokwari Strain SARS-CoV-2 Virus Phylogenetic Tree was reconstructed in Genious Prime software using the Neighbor-Joining method

3.1 Single Nucleotide Polymorphism (SNP) and Virus Variants

SNP and variant analysis was performed using the data bank available at the link (<https://usegalaxy.org/welcome/new>) and Pangolin version 1.3.1.7. Based on SNP analysis and variance, the SARS-CoV-2 virus sample from Manokwari, West Papua contained three variants, such as Delta (B.1.617.2), B.1.466.2, and Omicron (BA.1, BA.1.15, and BA.1.13.1). According to WHO classifying of variants, the SARS-CoV-2 virus of Manokwari is categorized as VOC and VUM (Table 2).

3.2 Phylogenetic Analysis

GISAID as gene bank provided phylogenetic analysis and a collection of data from 54 genomes of the SARS-CoV-2 virus in Indonesia and several other countries. Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Kappa (B.1.617.2), Epsilon (B.1.427), Eta (B.1.525), Iota (B.1.526), Lambda (C.37), Mu (B.1.621), Omicron (BA.1), B.1.177, 19B, and B.1.466.2 are the viral variants used. The tree is rooted

in the oldest virus, NC 045512.2, and was analyzed using a nucleotide length of 29,903 (Fig. 1).

According to the phylogenetic tree in Fig. 2, the West Papua Manokwari strain's SARS-CoV-2 virus variant consists of 10 clades, with the B.1.466.2 virus variant adjacent to the B.1.466.2 virus variants from Southeast Sulawesi and West Sumatra [1].

4 Discussions

Each life's genetic information is stored in its genome, and annotations are the first step in interpreting its sequence. The SARS-CoV-2 genome is approximately 29,903 kb in length. It also contains 5 structural proteins and 16 non-structural proteins. In this study, we worked to determine the characteristics of the SARS-CoV-2 virus's complete genome sequence in Manokwari, West Papua, from 48 samples that were subjected to whole genome sequencing analysis, 16 of which were not properly sequenced. This was influenced by the lengthy storage period. The delivery procedure.

The West Papua Manokwari virus strain had three variants in the analysis of variance, namely Delta (B.1.617.2), B.1.466.2, and Omicron (BA.1, BA.1.15 and BA.1.13.1). The Delta variant was discovered in India in October 2020, while the B.1.466.2 variant was discovered in Indonesia in November 2020, and the Omicron variant was discovered in Botswana, Africa in early November 2021. (WHO, 2021). According to the WHO variant classification, the SARS-CoV-2 virus, the Manokwari stain, is classified as a Variant of Concern (VOC) and a Variant Under Monitoring (VUM). VOC variants have increased transmission and caused negative changes in the epidemiology of SARS-CoV-2 infection, as well as increased virulence or clinical disease presentation. These variants are classified as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.617.2) (BA.1). The SARS-CoV-2, VUM variant is a variant with genetic changes that are thought to affect the virus's characteristics, with indications that it may pose a risk in the future, but the evidence for a phenotypic or epidemiological impact is currently unclear, it is still being studied, and more research is needed. B.1.466.2, B.1.429, B.1.1.523, B.1.619, B.1.620, B.1.526, B.1.525, B.1.617.1, B.1.318, C.1.2, B.1.640, AV.1, AT.1, P.2, P.3, R.1, B.1.1.519, C.36.3, B.1.214.2, B.1.427, and B.1630 are the VUM variants (WHO, 2021).

Furthermore, there are 1166 SNP, 602 missense, and 668 silent variants (Table 3). The Omicron variant virus sample contained more than 56 SNPs, whereas the B.1.466.2 variant virus sample contained the fewest, namely 26. This finding is consistent with that of (covariants.org, 2022), who discovered that the Omicron variant had the same mutations. More common than the Delta variant, and B.1.466.2 contains over 60 mutations. Following a characteristic analysis with the reference genome from Wuhan, China, it was discovered that the ORF1ab NSP3 gene region contained the most mutations in the ORF3 gene, ORF7 gene, N gene, and S gene. Cytosine-thymine 552 and Guanine-thymine 147 are the most common mutations. Both Cytosine - Thymine and Thymine - Cytosine, are synonyms but Guanine - Thymine mutations can change amino acids [4].

Table 3. Changes in the Nucleotide Bases of the SARS-CoV-2 Virus Manokwari strain, West Papua

No	ID Virus	Base changes (SNPs)											
		A-C	A-G	A-T	C-A	C-G	C-T	G-A	G-C	G-T	T-A	T-C	T-G
1	MKW_EPI_ISL_3151603	0	1	0	1	1	20	0	0	1	0	1	0
2	MKW_EPI_ISL_3151608	0	1	0	1	1	18	0	0	3	0	1	0
3	MKW_EPI_ISL_3151615	0	4	0	1	2	17	3	0	9	0	2	1
4	MKW_EPI_ISL_3151622	0	1	0	1	1	20	0	0	2	0	1	0
5	MKW_EPI_ISL_5022912	0	5	0	1	2	19	4	0	9	0	2	1
6	MKW_EPI_ISL_3151635	0	4	1	1	2	12	1	0	4	0	4	1
7	MKW_EPI_ISL_3151655	0	2	1	1	1	21	1	0	2	0	5	0
8	MKW_EPI_ISL_3151661	1	3	0	1	0	15	0	0	3	0	1	0
9	MKW_EPI_ISL_3278295	0	1	0	1	1	19	0	1	4	0	2	1
10	MKW_EPI_ISL_3151602	0	2	0	2	1	18	0	0	3	0	2	0
11	MKW_EPI_ISL_3151607	0	5	0	1	2	14	2	0	8	0	2	4
12	MKW_EPI_ISL_3151614	0	5	0	1	2	17	2	0	8	0	2	1
13	MKW_EPI_ISL_3151621	0	2	0	2	1	18	0	0	3	0	3	0
14	MKW_EPI_ISL_3151628	0	4	0	1	2	13	3	0	6	0	3	1
15	MKW_EPI_ISL_3151634	0	4	0	1	2	17	3	0	8	0	2	1
16	MKW_EPI_ISL_3151641	0	2	0	1	1	17	0	0	3	0	2	0
17	MKW_EPI_ISL_3151642	0	1	0	1	1	19	0	0	3	0	2	0
18	MKW_EPI_ISL_3151647	0	1	0	1	1	19	1	0	2	0	1	0
19	MKW_EPI_ISL_3151648	0	5	0	2	2	17	5	0	9	0	2	1
20	MKW_EPI_ISL_3151653	0	1	0	1	1	18	2	0	2	1	1	0
21	MKW_EPI_ISL_3151654	0	6	0	2	2	15	4	1	8	0	4	1
22	MKW_EPI_ISL_3151659	0	2	0	1	1	18	0	0	3	0	1	0
23	MKW_EPI_ISL_3151660	1	4	0	1	0	16	0	0	3	0	1	0
24	MKW_EPI_ISL_3151667	0	7	0	2	2	16	3	0	8	0	2	1
25	MKW_EPI_ISL_3151668	1	2	0	1	2	16	4	0	10	0	3	1
26	MKW_EPI_ISL_3151674	0	5	0	1	2	17	2	0	8	0	2	1
27	MKW_EPI_ISL-3151675	0	5	0	1	2	14	2	0	5	0	4	1
28	MKW_EPI_ISL-11994142	2	7	3	6	1	19	9	1	2	1	4	3
29	MKW_EPI_ISL-11994116	2	7	3	6	1	18	9	1	2	1	4	3
30	MKW_EPI_ISL-11994140	2	7	3	6	1	19	9	1	2	1	4	3
31	MKW_EPI_ISL-11994141	2	8	3	6	1	18	7	1	2	1	6	2
32	MKW_EPI_ISL-11994143	2	7	3	6	1	18	9	1	2	1	4	3

This finding is similar to the findings of Fibriani et al. (2021) in Bandung, who discovered mutations in the Delta variant (B.1.617.2), variant B.1.466.2, and variant B.1.470, with the most mutations in the genomic regions of spike protein, NSP3, nucleocapsid, NSP12, and ORF3a. A new mutation occurs in the E region of the gene for the Omicron variants (BA.1, BA.1.15, and BA.1.13.1). Because of this new mutation, the virus is no longer recognized by the majority of N-terminal domain (NTD) antibodies and receptors. RBDs are RNA-binding domains [5]. The envelope membrane protein (E) is a group of relatively small viral proteins that aid in the morphogenesis, assembly, and release of virions [6]. The Omicron variant has a much higher presentation in Indonesia than the Delta variant, according to data on (GISAID, 2022) on 23 May 2022, the Omicron variant reported in Indonesia is 11,283 while the Delta variant is 8,689, which is consistent with what was predicted by [7] in his research, which stated that the SARS-CoV-2 Omicron variant quickly replaced the Delta variant and spread throughout the world. 11,283 while the Delta variant is 8,689, which is consistent with what was predicted by [7] in his research, which stated that the SARS-CoV-2 Omicron variant quickly replaced the Delta variant and spread throughout the world, When compared to previous virus variants, the clinical symptoms of the Omicron variant were milder, as evidenced by a lower rate of hospitalization at the Hospital [8].

This finding is similar to the findings of Fibriani et al. (2021) in Bandung, who discovered mutations in the Delta variant (B.1.617.2), variant B.1.466.2, and variant B.1.470, with the most mutations in the genomic regions of spike protein, NSP3, nucleocapsid, NSP12, and ORF3a. A new mutation occurs in the E region of the gene for the Omicron variants (BA.1, BA.1.15, and BA.1.13.1). Because of this new mutation, the virus is no longer recognized by the majority of N-terminal domain (NTD) antibodies and receptors. RBDs are RNA-binding domains [5]. Random mutation followed by selection and recombination can cause genetic variation in the SARS-CoV-2 genome [9]. The high number of mutations in the S gene, particularly in the receptor binding domain (RBD) and the N-terminal domain (NTD), is most likely due to substitution selection that promotes viral adaptation, namely, changes in the structure of the spike protein that result in an increase in the host receptor or not being recognized. Thanks to antibodies [9]. Deletions may also occur as a result of selection for resistance to neutralizing antibodies [9]. Selection also causes the emergence of new mutations in other genes; for example, mutations in the E gene have been linked to increased immune shedding via suppression of the host's innate immune response [10].

For the SARS-CoV-2 virus variant, there are several key point mutations in the Spike protein; for the B.1.466.2 virus variant, it is located at N439K. Mutations in this region are linked to fitness and virulence, and they may confer a higher binding affinity to the human ACE2 receptor, allowing antibody-mediated immunity to escape [11]. The key mutation point in the Delta variant is at L452R, which is associated with increased binding to ACE2 and neutralizing antibody resistance, resulting in faster virus replication and increased virus transmission [9]. A Delta virus variant with mutations in the T19R, G142D, E156G region, and two deletions of F157 and R158 within the NTD has altered monoclonal antibody (mAb) recognition sites recognized by loops N1 and N3, allowing the virus to evade the antibody response [12]. In RBD, there are 11 mutations in the Omicron variant: G339D, S373P, S375F, K417N, N440K, S477N, T478K, E484A,

Q493R, Q498R, and N501Y. This mutation causes the virus to contribute significantly to changing the spectrum of the SARS-CoV-2 host in avoiding the immune response, as well as making the virus more infectious than the Delta variant [13]. While Omicron has mutations in the S375F, N501Y, P681H, D796Y, N764K, and N969K regions, resulting in a lower binding affinity for Spike-ACE2 compared to the Delta variant, Omicron (BA.2) has a strong binding affinity for Spike-ACE2 [14].

Although the SARS-CoV-2 mutation appears in the same gene, it indicates the virus's evolution to the vaccination program. In studies [15] and [16], the efficacy of two doses of BNT162b2 vaccine and chadox1 ncov-19 vaccine against Omicron was significantly lower than Delta; however, booster doses of mRNA vaccines have been shown to partially restore protection against Omicron, according to studies of neutralizing antibodies [9]. According to the phylogenetic tree in Fig. 9, the West Papua Manokwari strain of the SARS-CoV-2 virus has ten clades. Based on the virus variant, the West Papua Manokwari strain of the SARS-CoV-2 virus is divided into three large clades. The first clade is a variant of the B.1.466.2 virus in which the sample isolates with the ID EPI ISL 3151660 and EPI ISL 3151661 are identical, with a 100% bootstrap value. Based on this, those infected with EPI ISL 3151660 are the same as those infected with EPI ISL 3151661, and isolate samples with ID EPI ISL 3151602 and EPI ISL 3151621 have the same bootstrap value of 86%. When looking at the transmission in this first clade, which the epidemiological path of the virus that infects Manokwari, West Papua, generally passes through West Sumatra and Southeast Sulawesi.

The second clade is a Delta virus variant (B.1.617.2) in which the sample isolates have the same ID, EPI ISL 3151614 and EPI ISL 3151674, with a bootstrap value of 100%. Based on this, those infected with EPI ISL 3151614 are the same as those infected with EPI ISL 3151674, with the second clade still adjacent to the Indian Delta virus variant. The third clade is an Omicron virus variant in which samples of the West Papua Manokwari strain Omicron virus variant are still similar to the Botswana Omicron virus variant [17].

According to the guidelines of the Minister of Health Decree No HK.01.07/MENKES/4842/2021, it is necessary to continue identifying and characterizing the SARS-CoV-2 virus variant in a more widespread and consistent manner, both in terms of quantity and time of implementation.

5 Conclusion

The Manokwari West Papua virus SARS-CoV-2 strain has three variants such as Delta (B.1.617.2), B.1.466.2, and Omicron. The regions with the most mutations were the ORF1ab NSP3 gene region, the ORF3 gene, the ORF7 gene, the N gene, and the S gene, while the Omicron variant had a new mutation in the E gene.

Acknowledgments. We would like to acknowledge the support of The Ministry of Directorate General of Higher Education and Culture (Kemendikbudristek) Indonesia, have funded this research. We also acknowledge to the Indonesia Ministry of Health Research and Development (Kemenkes) for facilitating WGS equipment; to the Provincial General Hospital of West Papua, Indonesia for facilitating samples.

Authors' Contributions. Conceptualization: MK and MF; Methodology: MK, MF, HH, AP, and RU, Formal analysis and validation: MK, MF, AS, EM; Preparation: NCA, NT; Writing: MK, MF, and RD.

References

1. Cohen, Cheryl, Kl. Jackie, AV. Gottberg, ML. McMorrow, N. Wolter, JN. Bhiman, J. Moyes, MD Plessis, M. Carrim, A. Buys, NA. Martinson, K. Kahn, S. Tollman, and L. Lebina. 2021. SARS-CoV-2 Incidence, Transmission and Reinfection in a Rural and an Urban Setting: Results of the PHIRST-C Cohort Study, South Africa, 2020-2021. *MedRxiv* 1(165):1–13.
2. Cui, Zhen, P. Liu, N. Wang, L. Wang, K. Fan, Q. Zhu, K. Wang, R. Chen, R. Feng, Z. Jia, M. Yang, G. Xu, B. Zhu, W. Fu, T. Chu, L. Feng, Y. Wang, X. Pei, P. Yang, XS Xie, L. Cao, Y. Cao, and X. Wang. 2022. Structural and Functional Characterizations of Infectivity and Immune Evasion of SARS-CoV-2 Omicron. *Cell* 185(5):860-871.e13. <https://doi.org/10.1016/j.cell.2022.01.019>.
3. Fibriani, Azzania, R. Stephanie, AA. Alfiantie, ALF. Siregar, GAP. Pradani, N. Yamahoki, WS. Purba, CNC. Alamanda, E. Rahmawati, Rifky.
4. Gunadi, H. Wibawa, Marcellus, MS. Hakim, EW. Daniwijaya, LP. Rizki, etc. 2020. Full-Length Genome Characterization and Phylogenetic Analysis of SARS-CoV- 2 Virus Strains from Yogyakarta and Central Java, Indonesia. *PeerJ* 8:1– 15. <https://doi.org/10.7717/peerj.10575>
5. Hansen, GC. Holm, AB. Schelde, IR. Moustsen- Helm, HD. Emborg, TG. Krause, K. Mølbak, and P. Valentiner-Branth. 2021. Vaccine Effectiveness against SARS-CoV-2 Infection with the Omicron or Delta Variants Following a Two-Dose or Booster BNT162b2 or MRNA-1273 Vaccination Series: A Danish Cohort Study. *Oxygen in the Universe* iii–iv. <https://doi.org/10.1051/978-2-7598-2485-4-001>.
6. Illumina Inc. 2020. Illumina CovidSeq Test: Instructions for Use. *US Food and Drug Administration Website* (April 2021).
7. Kamaruddin, M., 2021. Modul Bahan Ajar: Virus SARS-CoV-2 untuk Mahasiswa Ilmu Laboratorium Klinik. ISBN: 9786236974087. UNIMUS Press, Semarang).
8. Kamaruddin, M., 2020. Genomic Surveillance: Genetic drift and environmental spreading dynamic of CoViD-19 in Indonesia. Online Webinar of IKABIO 2020. <https://doi.org/10.31219/osf.io/cn4tm>
9. W. Rachman, R. Robiani, and RB. Ristandi. 2021. Analysis of SARS-CoV-2 Genomes from West Java, Indonesia. *Viruses* 13(10):2097. <https://doi.org/10.3390/v13102097>.
10. Fisher, Dale, and D. Heymann. 2020. Q&A: The Novel Coronavirus Outbreak Causing COVID-19. *BMC Medicine* 18(1):18–20. <https://doi.org/10.1186/s12916-020-01533-w>.
11. Kumar, Suresh, K. Karuppanan, and G. Subramaniam. 2022. Omicron (BA.1) and Sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment. *Journal of Medical Virology* (June). <https://doi.org/10.1002/jmv.27927>.
12. Kumar, Suresh, Thiviya S. Thambiraja, K. Karuppanan, and G. Subramaniam. 2022. Omicron and Delta Variant of SARS-CoV-2: A Comparative Computational Study of Spike Protein. *Journal of Medical Virology* 94(4):1641–49. <https://doi.org/10.1002/jmv.27526>.
13. Lewin, Harris A., GE. Robinson, J. Kress, WJ. Baker, J. Coddington, KA. Crandall, R. Durbin, SV. Edwards, F. Forest, M. Thomas. Gilbert, M. Melissa, IV. Goldstein, Grigoriev, J. Kevin, Hackett, D. Haussler, ED. Jarvis, E. Warren, Johnson, A. Patrinos, S. Richards, J. Carlos Castilla-Rubio, MA. Van Sluys, Pamela S. Soltis, X. Xu, H. Yang, and G. Zhang. 2018. Earth

BioGenome Project: Sequencing Life for the Future of Life. *Proceedings of the National Academy of Sciences of the United States of America* 115(17):4325–33. <https://doi.org/10.1073/pnas.1720115115>.

14. Li, Shumin, L. Yuan, G. Dai, RA. Chen, DX. Liu, and TS. Fung. 2020. Regulation of the ER Stress Response by the Ion Channel Activity of the Infectious Bronchitis Coronavirus Envelope Protein Modulates Virion Release, Apoptosis, Viral Fitness, and Pathogenesis. *Frontiers in Microbiology* 10(January):1–14. <https://doi.org/10.3389/fmicb.2019.03022>.
15. M. Kamaruddin, AR. Sulpianti, Haerani, Erniawati, Jusni, Artita, A. Annatasia, N. Triananinsi. 2022. Analisis Pelaksanaan Pelayanan Persalinan Selama Pandemi CoViD-19 Berdasarkan Pengetahuan dan Sikap Ibu Bersalin. *Jurnal Kebidanan Malahayati*. 7(2): 626–633. <http://ejournalmalahayati.ac.id/index.php/kebidanan/article/view/5337>
16. L. Bernal, Jamie, N. Andrews, C. Gower, E. Gallagher, R. Simmons, S. Thelwall, J. Stowe, E. Tessier, N. Groves, G. Dabrera, R. Myers, CNJ. Campbell, G. Amirthalingam, M. Edmunds, M. Zambon, KE. Brown, S. Hopkins, M. Chand, and M. Ramsay. 2021. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine* 385(7):585–94.
17. Mohamadian, Malihe, H. Chiti, A. Shoghli, S. Biglari, N. Parsamanesh, and A. Esmaeilzadeh. 2021. COVID-19: Virology, Biology and Novel Laboratory Diagnosis. *Journal of Gene Medicine* 23(2):1–11. <https://doi.org/10.1002/jgm.3303>.

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

